Peter DeMuth
Fortune : 8 500 $ au 31/05/2026
Fortune : 8 500 $ au 31/05/2026
Peter DeMuth currently works at Elicio Therapeutics, Inc., as Chief Scientific Officer from 2022.
Dr. DeMuth also formerly worked at Elicio Therapeutics, Inc. (United States), as Chief Scientific Officer from 2022 to 2023.
Dr. DeMuth received his doctorate degree in 2013 from Massachusetts Institute of Technology and undergraduate degree in 2008 from the University of Maryland.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 09/04/2026 | 743 ( 0 % ) | 8 500 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2022 |
| Sociétés | Poste | Fin |
|---|---|---|
Elicio Therapeutics, Inc. (United States)
Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Directeur Technique/Scientifique/R&D | 01/06/2023 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Elicio Therapeutics, Inc. (United States)
Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Health Technology |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of Maryland
University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. BiotechnologyHealth Technology Develops cancer immunotherapies | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national